Literature DB >> 25754275

Ectopic Cushing's syndrome secondary to lung and mediastinal tumours -- report from a tertiary care centre in Iran.

Ali A Ghazi, Azizollah Abbasi Dezfooli, Alireza Amirbaigloo1, Abolghasem Daneshvar Kakhki, Farzaneh Mohammadi, Farrokh Tirgari, Marina Pourafkari.   

Abstract

INTRODUCTION: Ectopic Cushing`s syndrome (ECS) secondary to neuroendocrine tumours (NETs) of the lung and mediastinum are rarely encountered. In this study, we present our experience in Iran on 15 patients with ECS secondary to lung and mediastinal tumours over a period of 27 years.
MATERIAL AND METHODS: Since 1985, 15 patients with ECS secondary to lung and mediastinal tumours have been diagnosed and prospectively followed by the endocrinology team of Taleghani Hospital, Tehran, Iran. The clinical signs and symptoms, laboratory findings, radiological features, immunohistochemical characteristics, management strategies and outcome data are here presented.
RESULTS: There were six women and nine men, aged 26-70 years, all presenting with typical features of Cushing's syndrome. Based on histopathologic evaluations, four patients had small cell lung cancer (SCLC) and seven patients had pulmonary NETs, one patient had a thymic NET, and one case was diagnosed as a lung tumourlet. The mean ± SD serum cortisol, 24h urine free cortisol and plasma ACTH were 47.2 ± 20.5 μg/dL, 2,702 ± 5,439 μg/day, and 220 ± 147 pg/mL, respectively. Pulmonary lesions ranged in diameter from 1.1 to 4 cm (mean 1.9 ± 1.1 cm). One patient had a 10 cm mediastinal mass. The duration of follow up in these cases was between one month and seven years (mean 29.9 ± 27.5 months). The four patients with SCLC died within three months of diagnosis.
CONCLUSION: Our data demonstrates the protean clinical and laboratory manifestations of ECS secondary to lung and mediastinal tumours, the problems encountered in diagnosis, and the need for a multidisciplinary approach. This study confirms other series from Western Europe and North America that, unlike the SCLC patients who show a poor outlook, ECS secondary to lung carcinoids has a more favourable prognosis.

Entities:  

Mesh:

Year:  2015        PMID: 25754275     DOI: 10.5603/EP.2015.0002

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  6 in total

Review 1.  Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review.

Authors:  Andrea M Isidori; Emilia Sbardella; Maria Chiara Zatelli; Mara Boschetti; Giovanni Vitale; Annamaria Colao; Rosario Pivonello
Journal:  J Clin Endocrinol Metab       Date:  2015-09       Impact factor: 5.958

Review 2.  Ectopic cushing's syndrome due to corticotropin releasing hormone.

Authors:  Manouchehr Nakhjavani; Alireza Amirbaigloo; Soghra Rabizadeh; Fabio Rotondo; Kalman Kovacs; Ali A Ghazi
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 3.  Two types of ectopic Cushing syndrome or a continuum? Review.

Authors:  Marta Araujo Castro; Mónica Marazuela Azpiroz
Journal:  Pituitary       Date:  2018-10       Impact factor: 4.107

Review 4.  Ectopic Cushing syndrome in small cell lung cancer: A case report and literature review.

Authors:  Hang-Yu Zhang; Jun Zhao
Journal:  Thorac Cancer       Date:  2016-11-08       Impact factor: 3.500

5.  Klotho expression and nodal involvement as predictive factors for large cell lung carcinoma.

Authors:  Barbara Brominska; Piotr Gabryel; Donata Jarmołowska-Jurczyszyn; Małgorzata Janicka-Jedyńska; Andrzej Kluk; Maciej Trojanowski; Beata Brajer-Luftmann; Kosma Woliński; Rafał Czepczyński; Paweł Gut; Gabriel Bromiński; Przemysław Majewski; Wojciech Dyszkiewicz; Marek Ruchała
Journal:  Arch Med Sci       Date:  2018-06-01       Impact factor: 3.318

6.  Long-term Survival of a Patient with Small Cell Lung Cancer Secreting ADH and ACTH Simultaneously, Following the Prolonged Use of Amrubicin.

Authors:  Aya Kosuda; Toru Shirahata; Nasa Kudo; Yuki Uehara; Masayoshi Miyawaki; Aika Hagiwara; Rie Murakami; Ken Shimizu
Journal:  Intern Med       Date:  2019-09-11       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.